Print

Navidea Biopharmaceuticals (NEOP) Announces the Presentation of Data at Several Upcoming Scientific Meetings  
5/9/2012 11:44:32 AM

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical studies investigating Lymphoseek® (Kit for the Preparation of Technetium Tc 99m Tilmanocept for Injection) in head and neck cancer, breast cancer, and melanoma and from Phase 1/Phase 2 clinical trials of its Alzheimer’s Disease candidate, AZD4694, were accepted for presentation at several upcoming scientific and medical meetings in May. Details of the presentations are listed below.